Research

With its innovative Clinical Trials Network, influential annual meeting and high-impact journals, SNMMI encourages and facilitates research and science for the nuclear medicine and molecular imaging field. Learn more.

Clinical Trials Network

The Clinical Trials Network (CTN) provides tools and resources to promote faster, more cost-effective drug development and increase the availability and performance of molecular imaging radiopharmaceuticals for use in the clinic. Our Mission is to advance the use of molecular imaging agents in clinical trials through standardization of chemistry and imaging methodology. This includes using imaging radiopharmaceuticals during the course of drug development, as well as bringing new radiopharmaceuticals to regulatory approval. Programs developed over the past 5 years include a comprehensive registry of qualified imaging sites and radiopharmaceutical manufacturers, a robust scanner validation program, access to standardized imaging protocols and a very strong clinical research education curriculum.

LATEST NEWS

  • January 9, 2017Fear of Diagnostic Low-dose Radiation Exposure Is Overstated, Experts Assert
    In an article published in the January 2017 issue of "The Journal of Nuclear Medicine," researchers assert that exposure to medical radiation does not increase a person’s risk of getting cancer.
  • January 9, 2017New therapeutic agent shows promise for treating deadly type of prostate cancer
    A new therapeutic agent for radioligand therapy called lutetium-177-labeled PSMA-617 is showing promise in a German multi-center study for treating patients with metastatic castration-resistant prostate cancer. The research was recently published in "The Journal of Nuclear Medicine."
  • January 9, 2017Fear of diagnostic low-dose radiation exposure is overstated, experts assert
    In an article published in the January 2017 issue of "The Journal of Nuclear Medicine," researchers assert that exposure to medical radiation does not increase a person's risk of getting cancer. The long-held belief that even low doses of radiation, such as those received in diagnostic imaging, increase cancer risk is based on an inaccurate, 70-year-old hypothesis, according to the authors.
  • January 5, 2017New Therapeutic Agent Proves More Effective Treatment for Advanced Prostate Cancer
    A German multicenter study, initiated by the German Society of Nuclear Medicine, demonstrates that lutetium-177 (Lu-177)-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC). The study is published in the January 2017 issue of "The Journal of Nuclear Medicine" and is the featured article.
  • December 5, 20163D-Printed Kidney Phantoms Aid Nuclear Medicine Dosing Calibration
    In nuclear medicine, the goal is to keep radiation exposure at a minimum, while obtaining quality images. Optimal dosing for individual patients can be difficult to determine. That’s where 3D-printed organ models of varying size and shape could be of great use. In a study reported in the December issue of "The Journal of Nuclear Medicine," researchers at the University of Würzburg in Germany focused on kidneys to demonstrate that low-cost 3D printing techniques can be used for quantitative SPECT/CT imaging.
  • December 5, 20163-D printed kidney phantoms aid nuclear medicine dosing calibration
    In a study reported in the December issue of "The Journal of Nuclear Medicine," researchers at the University of Würzburg in Germany focused on kidneys to demonstrate that low-cost 3D printing techniques can be used for quantitative SPECT/CT imaging.
  • December 2, 2016Novel Anti-PSMA Imaging Agent Quickly Identifies Prostate Cancer Lesions
    New research demonstrates that a novel imaging agent can quickly and accurately detect metastasis of prostate cancer, even in areas where detection has previously been difficult. Published in the December issue of "The Journal of Nuclear Medicine," the Phase 1 dose-escalation study of Zr-89-desferrioxamine-IAB2M (Zr-89-Df-IAB2M), an anti-PSMA minibody, in patients with metastatic prostate cancer shows its effectiveness in targeting both bone and soft tissue lesions.
  • December 2, 2016New PET imaging agent detects metastatic prostate cancer
    Researchers at Memorial Sloan Kettering Cancer Center demonstrated that a new PET imaging agent can detect metastatic prostate cancer in regions that it has previously been difficult to spot. Results from the Phase 1 dose-escalation study of Zr-89-deferrioxamine-IAB2M were published in the December issue of "The Journal of Nuclear Medicine."

Preclinical Imaging

CMIIT’s mission is to engage the molecular imaging community and leverage the SNMMI infrastructure to advance the adoption of emerging molecular imaging technologies and probes in preclinical and clinical applications. One of the goals is to develop educational resources for a “translational researcher”. CMIIT will provide researchers with needed education and training on the “nuts and bolts” of translating and transitioning an agent or technique from pre-clinical research into the clinical practice such as tracer development, equipment, and funding.

The Nuclear Medicine Clinical Trial Group, LLC

Under the auspices of the Society of Nuclear Medicine and Molecular Imaging, the Nuclear Medicine Clinical Trial Group(NMCTG) assists industry partners and academic investigators in managing clinical research activities.  Its goals include ensuring quality imaging is conducted in drug or diagnostic clinical trials and providing training for molecular imaging professionals performing clinical research. Many of the programs established under the Clinical Trials Network, such as its robust Education Program, provide support to the NMCTG to help carry out its mission.